Breaking News

Thursday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ALB Albemarle $106.69 1.2 (1.14%) 14:27 09/20/18 09/20 14:27 09/20/18 14:27 Recommendations	Albemarle analyst commentary at Loop Capital » Loop Capital would still… Loop Capital would still be buyers of Albemarle. Loop Capital analyst Chris Kapsch said he would still be a buyer of Albemarle and views the stock as a compelling investment opportunity given the "decades-long runway" for lithium demand growth driven by the adoption of electric vehicles. Albemarle is among the more advantageously positioned lithium players when considering prospective growth, its sustainably competitive cost structure and its lithium chemistry "know-how," said Kapsch, who has a Buy rating and $130 price target on the stock. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Oct

Over a week ago
ALB Albemarle $100.61 (0.00%) 09:42 09/14/18 09/14 09:42 09/14/18 09:42 Recommendations	Albemarle analyst commentary at SunTrust » Albemarle valuation… Albemarle valuation underprices revenue growth sustainability, says SunTrust. SunTrust analyst James Sheehan kept his Buy rating and $115 price target on Albemarle, saying that the meetings he held with its management this week "reinforced" his bullish conviction on lithium supply/demand and the outlook for contract pricing in the near and medium term. The analyst notes that longer-term contracts requested by buyers "favor price stability" with a floor at current prices. Sheehan also maintains that the stock's current valuation multiple of 10-times his expected FY19 EBITDA is not giving the company "proper credit for the sustainability of its top line growth and robust lithium EBITDA margins". 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ALB Albemarle $98.58 -0.26 (-0.26%) 10:32 09/12/18 09/12 10:32 09/12/18 10:32 Conference/Events	Albemarle management to meet with SunTrust » Meeting to be held in… Meeting to be held in Baltimore on September 12 hosted by SunTrust. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Sep
HCLP Hi-Crush Partners $12.18 0.075 (0.62%) , GALT Galectin Therapeutics $5.68 -0.27 (-4.54%) … 08:45 09/11/18 09/11 08:45 09/11/18 08:45 Options	Largest borrow rate increases among liquid names » Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Hi Crush (HCLP) 19.37% +0.15, Galectin Therapeutics (GALT) 90.86% +0.11, Blackstone (BX) 1.51% +0.10, Albemarle (ALB) 0.45% +0.04, Pinduoduo (PDD) 7.09% +0.03, EWJ (EWJ) 0.34% +0.02, Direxion Daily Gold Miners Bull 3X Shares (NUGT) 2.70% +0.01, and Anheuser Busch (BUD) 1.60% +0.01. HCLP Hi-Crush Partners $12.18 0.075 (0.62%) GALT Galectin Therapeutics $5.68 -0.27 (-4.54%) BX Blackstone $35.89 0.64 (1.82%) ALB Albemarle $97.44 0.28 (0.29%) PDD Pinduoduo $19.80 0.25 (1.28%) EWJ iShares MSCI Japan Index Fund $56.81 0.13 (0.23%) NUGT Direxion Gold Miners Bull $11.21 -0.54 (-4.60%) BUD AB InBev $89.88 0.14 (0.16%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Sep 21 Sep 25 Sep 28 Oct
ALB Albemarle $97.44 0.28 (0.29%) 08:00 09/11/18 09/11 08:00 09/11/18 08:00 Recommendations	Albemarle analyst commentary at RBC Capital » Albemarle stock price… Albemarle stock price decline offers 'attractive' opportunity, says RBC Capital. RBC Capital analyst Arun Viswanathan is keeping his Outperform rating and $120 price target on Albemarle after his investor meetings with the company's management yesterday. The analyst notes that the 12% short interest reflects a market that is skeptical in Albermarle performance amid the spot price decline of lithium in China. However, Viswanathan believes that the stock price decline this year is an "attractive opportunity", with expected decoupling in the realized and spot price expected to yield "strong quarters" and multiple expansion. The analyst also expects Albemarle's other segments to generate cash, offsetting any further potential weakness in Lithium. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

GTT GTT Communications $42.35 2.225 (5.55%) , GERN Geron $6.07 0.11 (1.85%) … 08:45 09/10/18 09/10 08:45 09/10/18 08:45 Options	Largest borrow rate increases among liquid names » Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Direxion Brazil Bull (BRZU) 5.05% +1.41, GTT Communications (GTT) 4.53% +0.92, Geron (GERN) 46.84% +0.29, Ubiquiti (UBNT) 9.38% +0.16, Exxon Mobil (XOM) 0.41% +0.14, Alnylam (ALNY) 0.45% +0.09, Insys Therapeutics (INSY) 20.91% +0.02, Barrick Gold (ABX) 0.42% +0.02, Albemarle (ALB) 0.42% +0.01, and Dillard's (DDS) 1.69% +0.01. GTT GTT Communications $42.35 2.225 (5.55%) GERN Geron $6.07 0.11 (1.85%) UBNT Ubiquiti $89.55 -0.79 (-0.87%) XOM Exxon Mobil $81.84 1.38 (1.72%) ALNY Alnylam $108.88 -3.19 (-2.85%) INSY Insys Therapeutics $8.28 0.175 (2.16%) ABX Barrick Gold $10.05 0.12 (1.21%) ALB Albemarle $97.16 -0.53 (-0.54%) DDS Dillard's $73.49 -1.71 (-2.27%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Sep 12 Sep
FMC FMC Corporation $83.02 -2.48 (-2.90%) , ALB Albemarle $96.49 0.96 (1.00%) 08:58 09/05/18 09/05 08:58 09/05/18 08:58 Periodicals	Albemarle could buy FMC lithium division if IPO stumbles, Reuters says » Albemarle (ALB) executive… Albemarle (ALB) executive Eric Norris said that his company could buy FMC's (FMC) lithium division if the initial public offering of the unit stumbles, according to Reuters, citing comments made to investors at an event in June that have not previously been publicly disclosed. Reference Link FMC FMC Corporation $83.02 -2.48 (-2.90%) ALB Albemarle $96.49 0.96 (1.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Sep 06 Sep 11 Sep 06 Nov 03 Dec
UPS UPS $123.68 0.86 (0.70%) , QCOM Qualcomm $69.65 1.59 (2.34%) … 10:29 09/04/18 09/04 10:29 09/04/18 10:29 Upgrade	On The Fly: Top five analyst upgrades » Catch up on today's… Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. UPS UPS $123.68 0.86 (0.70%) QCOM Qualcomm $69.65 1.59 (2.34%) ALB Albemarle $97.00 1.47 (1.54%) UNVR Univar $28.04 0.21 (0.75%) BSX Boston Scientific $36.18 0.63 (1.77%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Sep 12 Sep
ALB Albemarle $95.53 0.45 (0.47%) 07:03 09/04/18 09/04 07:03 09/04/18 07:03 Upgrade	Albemarle rating change at SunTrust » Albemarle upgraded to Buy… Albemarle upgraded to Buy at SunTrust on 'stable' lithium margins. As reported earlier, SunTrust analyst James Sheehan upgraded Albemarle to Buy from Hold and raised his price target to $115 from $110, saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. Instead, the analyst contents that a "high degree of technical expertise needed to manufacture battery-quality grades for electric cars", and expects Albemarle to sustain its margins through FY20 due to its "favorable long term contracts". Sheehan sees upside to the valuation multiple for the stock once investors see "evidence that growing lithium capacity is not as ruinous as once feared". 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ALB Albemarle $95.53 0.45 (0.47%) 06:04 09/04/18 09/04 06:04 09/04/18 06:04 Upgrade	Albemarle rating change at SunTrust » Albemarle upgraded to Buy… Albemarle upgraded to Buy from Hold at SunTrust 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial